Spain’s long-awaited and hard-fought legislation to launch a medical cannabis market in the country has been slammed by pharmacists, patient advocacy groups and businesses.
The draft decree, which was published earlier this year by the Ministry of Health, was immediately criticized for its restrictive nature, preventing the country’s extensive network of local pharmacies from being able to prescribe and dismissing cannabis flower as an option for patients.
Under the government’s draft decree, Spain’s plan for medical cannabis use outlines four specific indications for its application: spasticity due to multiple sclerosis, severe refractory epilepsy, nausea and vomiting caused by chemotherapy, and chronic refractory pain.
But with the deadline for the second public consultation period on the proposals now passed, the industry has once again been left waiting to understand what shape Spain’s medical cannabis industry might take.
This item originally appeared on Business of Cannabis. The full story is available here.
